Ventas, Inc.
NYSE:VTRREIT - Healthcare Facilities
-$0.28 today
- Market cap
- $46.64B
- Beta
- 0.73
- P/E (TTM)
- 149.7
- EPS (TTM)
- $0.55
- Dividend yield
- 2.39%
Volume 3.72M
Average 4.09M
VTR EBITDA Margin
EBITDA as a percentage of revenue.
Ventas, Inc.NYSE: VTR
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin narrows to 36.5%
EBITDA Margin was 36.5% in Q2 FY2026, down 1.4 pp from a year earlier. On a trailing-twelve-month basis it was 38.5%, up 1.7 pp year over year. Over 3 fiscal years it widened by 2.1 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 29.4% for the fiscal year ending Dec 2026, down from 38.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 36.5%-7.6 pp QoQ
- Last fiscal yearDec 2025
- 38.4%+1.4 pp YoY
- LTMJun 2026
- 38.5%+1.7 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -1.4 pp | +2.6 pp | +4.0 pp |
| 1 year | +1.4 pp | -9.0 pp | -10.4 pp |
| 3 years | +2.1 pp | -14.9 pp | -17.0 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 38.4%
- Year-over-year change
- +1.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.4% | +1.4pp |
| FY2024 | 2024-12-31 | 37.0% | -0.8pp |
| FY2023 | 2023-12-31 | 37.8% | +1.5pp |
| FY2022 | 2022-12-31 | 36.3% | -2.3pp |
| FY2021 | 2021-12-31 | 38.6% | — |
EBITDA Margin vs competitors
How VTR compares with its peers on the latest reported figures
- VTR's LTM Jun 2026 EBITDA Margin of 38.5% is the 8th highest of the 11 companies compared; the peer median is 83.8%.
- Its year-over-year change of +1.7 pp is the 7th highest of 10, against a peer median of +20.3 pp.
- Over three fiscal years its change of +2.1 pp compares with a peer median of -6.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 186.2% | +107.9 pp | +10.3 pp | |
| LTM Sep 2026 | 152.0% | +104.9 pp | -21.7 pp | |
| LTM Jun 2026 | 112.1% | +20.3 pp | -16.4 pp | |
MPTMedical Properties Trust, Inc. | LTM Jun 2026 | 103.2% | +116.1 pp | -52.3 pp |
| LTM Sep 2026 | 89.0% | -27.1 pp | +58.1 pp | |
| LTM Sep 2026 | 78.5% | +24.2 pp | -16.5 pp | |
| LTM Jun 2026 | 45.5% | -19.4 pp | +24.3 pp | |
| LTM Jun 2026 | 38.5% | +1.7 pp | +2.1 pp | |
NHPNational Healthcare Properties, Inc. (NHP) | LTM Dec 2025 | 24.6% | — | +7.8 pp |
| LTM Sep 2026 | 24.3% | -11.8 pp | -13.6 pp | |
| LTM Sep 2026 | 18.1% | +3.4 pp | +1.5 pp | |
| Peer median (excluding VTR) | 83.8% | +20.3 pp | -6.1 pp | |
Competitors are the stored peer set for VTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.83B | 4.13B | 4.5B | 4.92B | 5.83B |
| Cost of Revenue | 2.09B | 2.28B | 2.56B | 2.83B | 6.18B |
| Gross Profit | 1.74B | 1.85B | 1.94B | 2.1B | (344.22M) |
| Gross Margin | 45.4% | 44.7% | 43.1% | 42.6% | -5.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 129.76M | 144.87M | 148.88M | 162.99M | 177.4M |
| Operating Expenses | 1.32B | 1.36B | 1.52B | 1.42B | (1.17B) |
| Depreciation & Amortization | 978M | 1.09B | 1.17B | 1.17B | 1.38B |
| EBITDA | 1.48B | 1.5B | 1.7B | 1.82B | 2.24B |
| EBITDA Margin | 38.6% | 36.3% | 37.8% | 37.0% | 38.4% |
| Operating Income | 421.43M | 483.85M | 415.51M | 681.23M | 826.81M |
| Operating Margin | 11.0% | 11.7% | 9.2% | 13.8% | 14.2% |
| Interest Income | 0 | 0 | 0 | 0 | 22.59M |
| Interest Expense | 440.09M | 467.56M | 574.11M | 602.84M | 612.25M |
| Other Income / Expenses | (360.05M) | (541.7M) | (455.35M) | (630.65M) | (579.44M) |
| Income Before Tax | 61.39M | (57.86M) | (39.84M) | 50.58M | 247.37M |
| Pre-Tax Margin | 1.6% | -1.4% | -0.9% | 1.0% | 4.2% |
| Income Tax Expense | 4.83M | (16.93M) | (9.54M) | (37.78M) | (14.15M) |
| Net Income | 49.01M | (47.45M) | (40.97M) | 81.15M | 251.38M |
| Net Margin | 1.3% | -1.1% | -0.9% | 1.6% | 4.3% |
| EPS (Basic) | 0.13 | (0.13) | (0.10) | 0.20 | 0.55 |
| EPS (Diluted) | 0.13 | (0.13) | (0.10) | 0.19 | 0.54 |
| Weighted Avg Shares | 382.79M | 373.37M | 401.81M | 411.77M | 455.08M |
| Weighted Avg Shares (Diluted) | 386.3M | 373.37M | 405.67M | 416.37M | 462.62M |
Ventas, Inc.
NYSE:VTR
Intrinsic Alpha fair value
Locked
Current Price
$88.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.